SCLS
MCID: CPL003
MIFTS: 54

Capillary Leak Syndrome (SCLS)

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Immune diseases, Rare diseases

Aliases & Classifications for Capillary Leak Syndrome

MalaCards integrated aliases for Capillary Leak Syndrome:

Name: Capillary Leak Syndrome 12 20 58 54 44 15 17 70
Systemic Capillary Leak Syndrome 20 58 17
Capillary Leak Syndrome with Monoclonal Gammopathy 20 70
Clarkson Disease 20 58
Scls 20 58
Periodic Systemic Capillary Leak Syndrome 20
Capillary Hyperpermeability Syndrome 58
Idiopathic Capillary Leak Syndrome 58

Characteristics:

Orphanet epidemiological data:

58
systemic capillary leak syndrome
Inheritance: Not applicable; Prevalence: <1/1000000 (Worldwide); Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases


Summaries for Capillary Leak Syndrome

GARD : 20 Systemic capillary leak syndrome (SCLS) is a condition in which fluid and proteins leak out of tiny blood vessels, into surrounding tissues. This can result in dangerously low blood pressure (hypotension), hypoalbuminemia, and a decrease in plasma volume ( hemoconcentration ). Initial symptoms may include fatigue, nausea, abdominal pain, extreme thirst, and sudden increase in body weight. Episodes of SCLS vary in frequency, with some people having one episode in their lifetime, and others having several per year. The severity also varies, and the condition can be fatal. In many cases the cause is not known (idiopathic SCLS). Some people with SCLS report having had an infection (such as a virus ) before the episode. Some cases of capillary leak are associated with various conditions of the heart, kidney, or liver. Treatment during an episode may involve stabilizing the airway and breathing, and infusion of fluids, medications, or blood products. Periodic infusions or the use of certain medications may be used to prevent future episodes.

MalaCards based summary : Capillary Leak Syndrome, also known as systemic capillary leak syndrome, is related to cardiogenic shock and toxic shock syndrome. An important gene associated with Capillary Leak Syndrome is IL2 (Interleukin 2), and among its related pathways/superpathways are Innate Immune System and Pathways in cancer. The drugs Morphine and Propranolol have been mentioned in the context of this disorder. Affiliated tissues include endothelial, skin and bone marrow, and related phenotypes are pedal edema and leukocytosis

Wikipedia : 73 Capillary leak syndrome is characterized by the escape of blood plasma through capillary walls, from the... more...

Related Diseases for Capillary Leak Syndrome

Diseases related to Capillary Leak Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 514)
# Related Disease Score Top Affiliating Genes
1 cardiogenic shock 30.9 IL6 ADM
2 toxic shock syndrome 30.8 IL6 IL2 EDNRA CXCL8 C1S
3 adult respiratory distress syndrome 30.7 IL6 ELANE CXCL8 C4A
4 angioedema 30.7 SERPING1 C4A C3 C1S
5 enterocolitis 30.6 IL6 CXCL8 C3
6 fasciitis 30.6 IL6 IL2 CXCL8
7 perinatal necrotizing enterocolitis 30.6 IL6 CXCL8 ALB
8 brucellosis 30.5 IL6 IL2 CXCL8
9 kawasaki disease 30.5 IL6 ELANE ALB ADM
10 hydrops, lactic acidosis, and sideroblastic anemia 30.4 SERPING1 C1S ALB
11 pericarditis 30.4 IL6 CXCL8 ALB
12 engraftment syndrome 30.4 CXCL8 CSF2
13 endocarditis 30.3 IL6 CXCL8 ALB
14 diarrhea 30.2 IL6 IL2 CXCL8 C3 ALB
15 acquired angioedema 30.2 SERPING1 C3 C1S
16 necrotizing fasciitis 30.2 IL6 IL2 CXCL8 ALB
17 pneumonia 30.2 IL6 ELANE CXCL8 ALB ADM
18 thrombocytopenia 30.1 IL6 IL2 CXCL8 CSF2 C3 ALB
19 peritonitis 30.1 IL6 ELANE CXCL8 ALB
20 vasculitis 30.1 IL6 ELANE C3 C1S
21 hereditary angioedema 30.0 SERPING1 ELANE C4A C1S ADM
22 kidney cancer 30.0 IL2 CXCL8 CSF2 ALB
23 monoclonal gammopathy of uncertain significance 30.0 IL6 ICOSLG CD19
24 neutropenia 29.9 IL6 IL2 ELANE CXCL8 CSF2 ALB
25 pneumocystosis 29.8 IL6 IL2 CD8A ALB
26 aspergillosis 29.8 IL6 IL15 ELANE CXCL8 CSF2
27 meningitis 29.8 IL6 IL2 CXCL8 CSF2 C3 ALB
28 pulmonary hypertension 29.8 IL6 ELANE EDNRA CXCL8 ALB ADM
29 pancytopenia 29.6 IL6 CSF2 CD8A CD19
30 respiratory failure 29.5 IL6 ELANE CXCL8 CD8A ALB ADM
31 deficiency anemia 29.3 IL6 ICOSLG CSF2 CD8A CD19 ALB
32 connective tissue disease 29.3 IL6 IL2 ICOSLG EDNRA CXCL8 CD8A
33 exanthem 29.3 IL6 IL2 ICOSLG CXCL8 CSF2 CD8A
34 peripheral nervous system disease 29.1 IL6 IL2 ICOSLG CXCL8 CSF2 CD8A
35 myeloma, multiple 28.7 IL6 IL2 IL15 ICOSLG CXCL8 CSF2
36 leukemia, acute lymphoblastic 28.5 IL3RA IL2 ICOSLG CSF2 CD8A CD22
37 lymphoma, non-hodgkin, familial 28.3 IL6 IL2 IL15 ICOSLG CSF2 CD8A
38 malaria 28.3 IL6 IL2 IL15 ICOSLG ELANE CXCL8
39 leukemia, chronic lymphocytic 28.1 IL6 IL3RA IL2 ICOSLG CSF2 CD8A
40 dengue disease 11.2
41 compartment syndrome 10.7
42 pulmonary edema 10.6
43 metabolic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 10.5
44 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.5
45 noma 10.5 CXCL8 ALB
46 koro 10.4 EDNRA ALB
47 idiopathic anterior uveitis 10.4 IL6 CXCL8
48 acute transverse myelitis 10.4 IL6 CXCL8
49 acute gonococcal cervicitis 10.4 IL6 CXCL8
50 bullous impetigo 10.4 IL6 EDNRA

Graphical network of the top 20 diseases related to Capillary Leak Syndrome:



Diseases related to Capillary Leak Syndrome

Symptoms & Phenotypes for Capillary Leak Syndrome

Human phenotypes related to Capillary Leak Syndrome:

58 31 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pedal edema 58 31 hallmark (90%) Very frequent (99-80%) HP:0010741
2 leukocytosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001974
3 hypotension 58 31 frequent (33%) Frequent (79-30%) HP:0002615
4 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
5 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
6 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
7 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
8 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
9 pancreatitis 58 31 frequent (33%) Frequent (79-30%) HP:0001733
10 pulmonary edema 58 31 frequent (33%) Frequent (79-30%) HP:0100598
11 rhinorrhea 58 31 frequent (33%) Frequent (79-30%) HP:0031417
12 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
13 venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004936
14 abnormal renal tubule morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0000091
15 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
16 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
17 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
18 myocarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012819
19 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
20 oliguria 58 31 occasional (7.5%) Occasional (29-5%) HP:0100520
21 multiple myeloma 58 31 occasional (7.5%) Occasional (29-5%) HP:0006775
22 cardiorespiratory arrest 58 31 occasional (7.5%) Occasional (29-5%) HP:0006543
23 constitutional symptom 58 Frequent (79-30%)

GenomeRNAi Phenotypes related to Capillary Leak Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ALB C3 C4A CD22 CXCL8 IL3RA

MGI Mouse Phenotypes related to Capillary Leak Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 ADM ALB C3 CD19 CD22 CD8A
2 hematopoietic system MP:0005397 10.13 ADM C3 CD19 CD22 CD8A CSF2
3 immune system MP:0005387 10.1 ADM ALB C3 CD19 CD22 CD8A
4 endocrine/exocrine gland MP:0005379 10.07 ADM ALB C3 CD8A CSF2 EDNRA
5 mortality/aging MP:0010768 9.97 ADM ALB C3 CD19 CD22 CD8A
6 neoplasm MP:0002006 9.5 ALB CD19 CSF2 ELANE IL2 IL6
7 renal/urinary system MP:0005367 9.28 ADM ALB C3 CD19 CD8A CSF2

Drugs & Therapeutics for Capillary Leak Syndrome

Drugs for Capillary Leak Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Morphine Approved, Investigational Phase 2 57-27-2 5288826
2
Propranolol Approved, Investigational Phase 2 525-66-6 4946
3 Anti-Arrhythmia Agents Phase 2
4 Adrenergic beta-Antagonists Phase 2
5 Vasodilator Agents Phase 2
6 Narcotics Phase 2
7 Adrenergic Antagonists Phase 2
8 Analgesics Phase 2
9 Analgesics, Opioid Phase 2
10 Adrenergic Agents Phase 2
11 Antihypertensive Agents Phase 2
12 Neurotransmitter Agents Phase 2
13
Epinephrine Approved, Vet_approved 51-43-4 5816
14
Racepinephrine Approved 329-65-7 838
15
Tazobactam Approved 89786-04-9 123630
16
Vancomycin Approved 1404-90-6 441141 14969
17
Piperacillin Approved 66258-76-2 43672
18
Meropenem Approved, Investigational 96036-03-2, 119478-56-7 64778 441130
19
Amoxicillin Approved, Vet_approved 26787-78-0 33613
20 Epinephryl borate
21 Pharmaceutical Solutions
22 Ophthalmic Solutions
23 Anti-Bacterial Agents
24 Antibiotics, Antitubercular
25 Anti-Infective Agents
26 Clavulanic Acids
27 Immunotoxin HA22
28 Immunoglobulins
29 Antibodies
30 Antibodies, Monoclonal

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Contribution of COMT Haplotypes in Propranolol Analgesic Efficacy for Treating Post-surgical Pain After Laparoscopic Hemicolectomy Suspended NCT02511483 Phase 2 Propranolol PO;IV-PCA morphine;Placebo PO
2 Safety and Feasibility of Cultivated Autologous Limbal Stem Cells (cLSC) for Limbal Stem Cell Deficiency Recruiting NCT03957954 Phase 1
3 Characterization of Endothelial Dysfunction as a Function of Hyperaemia of the Brachial Artery During Cardiac Surgery Unknown status NCT02853682
4 Hospital Clínic Barcelona Unknown status NCT03306459
5 Monitoring the IMmUological TOXicity of Drugs Completed NCT03480529 drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom
6 Topical Autologous Serum Eye Drops Combined With Silicone Hydrogen Lenses for theTreatment of Corneal Epithelial Defects Completed NCT02291731 Continuous use of topical autologous serum
7 Bioelectrical Impedance Analysis as a Bedside Tool to Estimate Volume of Distribution of Hydrophilic Antimicrobials in Critically Ill Patients Completed NCT03410771 Monitor antibiotic exposure (PK profile)
8 Comparison of Psychological Symptoms in Patients With Behcet's Disease and Control Patients by Symptom Check List 90-Revised (SCL-90-R) Completed NCT00699985
9 US Post-Marketing Retrospective Observational Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(TM) Recruiting NCT04125290
10 Studies in the Pathogenesis of Systemic Capillary Leak Syndrome Recruiting NCT00936325
11 A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta Recruiting NCT04253015
12 Psychiatric Consultation for COVID-19 Patients Not yet recruiting NCT04395872
13 Psychological Distress in Outpatient Oncological Rehabilitation Not yet recruiting NCT04324320
14 A Prospective Single Center Open Label Study Assessing Intraocular Pressure Measurements Using a Novel Sensing Contact Lens-based Device as Compared to Standard Tonometry, in Open Angle Glaucoma and Ocular Hypertensive Patients Not yet recruiting NCT04024293
15 Comparative Study of Pathophysiological Mechanisms and Bronchial Response in Occupational Asthma to Wheat Flour and Quaternary Ammonium Compounds During Standardized Bronchial Provocation Tests Terminated NCT01783873

Search NIH Clinical Center for Capillary Leak Syndrome

Cochrane evidence based reviews: capillary leak syndrome

Genetic Tests for Capillary Leak Syndrome

Anatomical Context for Capillary Leak Syndrome

MalaCards organs/tissues related to Capillary Leak Syndrome:

40
Endothelial, Skin, Bone Marrow, Eye, Kidney, Lung, Liver

Publications for Capillary Leak Syndrome

Articles related to Capillary Leak Syndrome:

(show top 50) (show all 741)
# Title Authors PMID Year
1
Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome. 20 61
28602874 2017
2
The response of antithrombin III activity after supplementation decreases in proportion to the severity of sepsis and liver dysfunction. 61 54
18496242 2008
3
Left posterior fascicular block due to high-dose interleukin-2. 54 61
18664608 2008
4
Cytokine-associated angioedema syndromes including episodic angioedema with eosinophilia (Gleich's Syndrome). 54 61
17085290 2006
5
Validation of C1-esterase inhibitor therapy in severe capillary leak syndrome by monitoring of extravascular lung water. 61 54
14727019 2004
6
[Idiopathic anaphylaxis]. 61 54
15015747 2004
7
Managing toxicities of high-dose interleukin-2. 61 54
12469935 2002
8
Symptomatic neurological epidural metastasis with interleukin-2 therapy in metastatic renal cell carcinoma. 54 61
12400987 2002
9
Interleukin-2 as a therapeutic agent. 61 54
11837757 2001
10
Anticancer drug-induced kidney disorders. 61 54
11219485 2001
11
Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2. 54 61
11022123 2000
12
Pulmonary infiltrates after cytokine therapy for stem cell transplantation. Massive deposition of eosinophil major basic protein detected by immunohistochemistry. 61 54
10508829 1999
13
Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. 61 54
10554800 1999
14
Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates. 61 54
9383227 1997
15
Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. 54 61
9815532 1997
16
Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. 54 61
8674057 1996
17
Transcapillary forces of the subcutaneous tissue in patients treated with interleukin-2 and alpha-interferon: no capillary protein leak syndrome? 61 54
9414399 1996
18
The release of interleukin-8 during intravenous bolus treatment with interleukin-2. 54 61
7696165 1994
19
Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. 61 54
8012963 1994
20
Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation. 54 61
8110879 1994
21
Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. 61 54
8439951 1993
22
[Anatomopathological findings correlated with high-dose recombinant interleukin-2. Review of the literature and description of 2 autopsy cases]. 61 54
1491889 1992
23
Interleukin-2 therapy enhances salicylate oxidation by blood granulocytes. 54 61
1954382 1991
24
Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. 61 54
1884020 1991
25
[Interleukin immunotherapy of progression]. 61 54
1830670 1991
26
Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity. 54 61
1760811 1991
27
Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome. 61 54
2093734 1990
28
Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state. 61 54
2224143 1990
29
[The effect of corticosteroid on lymphokine-activated killer (LAK) activity and the change of membrane antigen phenotype on PBMC after IL2 incubation with reference to the evaluation in vitro]. 61 54
2376610 1990
30
Effect of human recombinant interleukin-2 on isolated rabbit femoral artery and porcine coronary artery and vein. 54 61
2282064 1990
31
Pathophysiology of cytokines. 61 54
2201818 1990
32
Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. 61
33739343 2021
33
The effect of tetrastarch solution for capillary leak syndrome following allogeneic hematopoietic stem cell transplantation: A report of 2 cases. 61
33747410 2021
34
Plasma filtration with dialysis for the treatment of capillary leak syndrome occurring secondary to surgery for colon cancer-related perforating peritonitis. 61
33768874 2021
35
Characteristics and Outcome of Severe Mycoplasma pneumoniae Pneumonia Admitted to PICU in Shanghai: A Retrospective Cohort Study. 61
33786442 2021
36
Phase 2 study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. 61
33792128 2021
37
Clinical features of 47 secondary hemophagocytic lymphohistiocytosis patients complicated with capillary leak syndrome. 61
33037588 2021
38
Near-fatal poisoning after ricin injection. 61
32475181 2021
39
Refractory severe idiopathic systemic capillary leak syndrome successfully treated with bevacizumab: a case report. 61
33550460 2021
40
Cerebral Involvement in Systemic Capillary Leak Syndrome. 61
33431729 2021
41
Idiopathic systemic capillary leak syndrome (Clarkson's disease) presenting with recurrent hypovolemic shock. 61
33749696 2021
42
Clarkson's Disease Episode or Secondary Systemic Capillary Leak-Syndrome: That Is the Question! 61
33422212 2021
43
Pulmonary capillary leak syndrome following COVID-19 virus infection. 61
32519786 2021
44
A new diagnosis of systemic capillary leak syndrome in a patient with COVID-19. 61
32940700 2021
45
Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. 61
32959985 2021
46
Capillary leak syndrome induced by neoadjuvant cisplatin and gemcitabine in a patient with bladder cancer. 61
33101987 2021
47
Renal replacement therapy with a cytokine-adsorbing hemofilter after neonatal open-heart surgery. 61
33416978 2021
48
Extensive leukoencephalopathy associated with idiopathic capillary leak syndrome: report of a case with neuropathology. 61
33411202 2021
49
Drug-induced peripheral oedema: An aetiology-based review. 61
33506982 2021
50
Hypoalbuminemia in COVID-19: assessing the hypothesis for underlying pulmonary capillary leakage. 61
33411411 2021

Variations for Capillary Leak Syndrome

Expression for Capillary Leak Syndrome

Search GEO for disease gene expression data for Capillary Leak Syndrome.

Pathways for Capillary Leak Syndrome

Pathways related to Capillary Leak Syndrome according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 IL6 IL3RA IL2 IL15 ICOSLG ELANE
2 12.71 IL6 IL3RA IL2 IL15 EDNRA CXCL8
3
Show member pathways
12.67 IL6 IL2 IL15 ICOSLG CXCL8 CD8A
4
Show member pathways
12.29 IL6 IL3RA IL2 IL15 CSF2
5 12.25 IL6 IL2 IL15 CSF2
6 12.18 IL6 ELANE CXCL8 CSF2
7
Show member pathways
12.07 SERPING1 C4A C3 C1S
8 12.02 SERPING1 C4A C3 C1S
9 11.99 IL6 IL2 CXCL8 CD8A
10 11.97 CD8A CD22 CD19 C3
11 11.8 C4A C3 C1S
12
Show member pathways
11.78 IL6 CXCL8 CSF2
13 11.75 IL6 IL15 CXCL8 CSF2
14 11.73 IL6 IL3RA CSF2 CD8A CD22 CD19
15
Show member pathways
11.71 C4A C3 C1S
16 11.7 IL2 IL15 CD8A
17
Show member pathways
11.67 IL2 CXCL8 CSF2
18 11.67 IL6 IL2 CXCL8 CSF2
19 11.57 IL6 CXCL8 CSF2
20
Show member pathways
11.53 IL6 IL2 CXCL8 CSF2
21 11.52 IL6 CXCL8 C3
22 11.51 SERPING1 IL6 CXCL8 C4A C3 C1S
23 11.44 IL6 CXCL8 CSF2
24 11.3 IL6 IL3RA IL2 CSF2 CD8A CD19
25 11.29 IL6 IL3RA IL2 IL15 CSF2 CD8A
26
Show member pathways
11.26 IL2 IL15 CSF2
27 11.13 IL6 IL2 IL15 CSF2
28 10.93 IL6 IL2 IL15 CXCL8 CSF2

GO Terms for Capillary Leak Syndrome

Cellular components related to Capillary Leak Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 SERPING1 IL6 IL2 IL15 ELANE CXCL8
2 external side of plasma membrane GO:0009897 9.65 IL3RA ICOSLG CD8A CD22 CD19
3 blood microparticle GO:0072562 9.55 SERPING1 C4A C3 C1S ALB
4 extracellular space GO:0005615 9.4 SERPING1 IL6 IL2 IL15 ELANE CXCL8

Biological processes related to Capillary Leak Syndrome according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.96 IL6 IL2 IL15 CSF2 ADM
2 cellular protein metabolic process GO:0044267 9.83 IL6 C4A C3 ALB
3 regulation of immune response GO:0050776 9.81 CD8A CD22 CD19 C3
4 cytokine-mediated signaling pathway GO:0019221 9.8 IL6 IL3RA IL2 CXCL8 CSF2
5 inflammatory response GO:0006954 9.8 IL6 IL15 CXCL8 C4A C3 ADM
6 immune system process GO:0002376 9.76 SERPING1 IL2 ICOSLG CD8A CD19 C4A
7 complement activation, classical pathway GO:0006958 9.73 SERPING1 C4A C3 C1S
8 positive regulation of T cell proliferation GO:0042102 9.67 IL6 IL2 IL15
9 neutrophil activation GO:0042119 9.57 IL15 CXCL8
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 IL6 IL2 IL15 CSF2
11 positive regulation of immune response GO:0050778 9.55 IL15 ELANE
12 negative regulation of chemokine production GO:0032682 9.54 IL6 ELANE
13 positive regulation of interleukin-17 production GO:0032740 9.54 IL6 IL2 IL15
14 immune response GO:0006955 9.5 IL6 IL2 IL15 CXCL8 CSF2 CD8A
15 positive regulation of apoptotic cell clearance GO:2000427 9.48 C4A C3
16 positive regulation of tissue remodeling GO:0034105 9.46 IL2 IL15
17 regulation of complement activation GO:0030449 9.02 SERPING1 CD19 C4A C3 C1S

Molecular functions related to Capillary Leak Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 IL6 IL2 IL15 CXCL8 CSF2

Sources for Capillary Leak Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....